SRPT Stock Analysis: Buy, Sell, or Hold?
SRPT - Sarepta Therapeutics,, Inc. Common Stock
$18.79
-0.43 (-2.24%)
▼
5d:
+3.81%
30d:
+18.32%
90d:
+10.79%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When SRPT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SRPT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SRPT shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.51
Based on -18.8% avg growth
INTRINSIC VALUE TODAY
$3.42
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 6.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SRPT is currently trading at $18.79, which is considered extended relative to its 30-day fair value range of $15.80 to $18.37. From a valuation perspective, the stock is trading at a premium (Forward PE: 7.5) compared to its historical average (6.7). At these levels, the market is pricing in 3.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRPT is in a strong downtrend. Immediate support is located at $16.38, while resistance sits at $20.19.
Market Sentiment: SRPT scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.09 (+14.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SRPT is in a strong downtrend. Immediate support is located at $16.38, while resistance sits at $20.19.
Market Sentiment: SRPT scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.09 (+14.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.80 -
$18.37
Company Quality Score
26/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
27.1%
Protect Your Profits
Holding SRPT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($22.09)
- NEUTRAL: Market pricing in 3.8% annual earnings growth - fairly valued
- WARNING: Composite score 26/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$15.80 -
$18.37
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.38
Resistance Level
$20.19
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.47
Wall Street Target
$22.09
(+14.9%)
Revenue Growth (YoY)
-34.3%
Earnings Growth (YoY)
2663.8%
Profit Margin
-6.9%
Valuation Premium vs History
+3.8% premium
PE vs Historical
7.5 vs 6.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.8%
(market-implied from PE analysis)
1-Year Target
$19.95
(+4%)
2-Year Target
$20.71
(+8%)
3-Year Target
$21.50
(+12%)
3-Yr Target (if PE normalizes)
(PE: 7→7)
PE COMPRESSION
$19.27
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: -41.5%)
$37.63
(+96%)
Base:
(SPY PE: 7.5, Growth: -41.5%)
$14.01
(-27%)
Bear:
(PE: 6.4, Growth: -41.5%)
$11.91
(-38%)
Share & Embed Analysis
Last updated: August 22, 2026 8:01 PM ET
Data refreshes hourly during market hours. Next update: 9:01 PM
Data refreshes hourly during market hours. Next update: 9:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRPT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Stephen Mayo
SELL
7239 shares
2026-03-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 54 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
Advanced SRPT Option Strategies
Professional options setups generated by AI based on today's SRPT price and gamma walls.
